Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs MEDVidi

Claya
Graded #267

Higher grade

vs+4.799999999999997
MEDVidi
Graded #384

Lower grade

The verdict

Claya takes it — 62.8/100 to 58/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMEDVidi +3
42
45
Dose & formulationClaya +22
75
53
Clinical oversightClaya +5
82
77
Labs & monitoringMEDVidi +9
53
62
FulfillmentClaya +8
67
59
Contract termsClaya +6
61
55
Claya · left barMEDVidi · right bar

The numbers

MetricClayaMEDVidi
WeighScore62.8/10058/100
GradeCC
Scorecard rank#267#384
Semaglutide$299/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Claya

Graded #267 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
MEDVidi

Graded #384 · C

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard